{ "entity_id": "B-002591", "folder": "Pharmaceutical-Services-Federal-Committee-of-Inquiry", "name": "Pharmaceutical Services Federal Committee of Inquiry", "type": "Statutory Body", "jurisdiction": "Commonwealth", "portfolio": "Health, Disability and Ageing", "website": "https://www.pbs.gov.au/info/healthpro/pharmaceutical-services-federal-committee-inquiry", "data_status": "partial", "completeness": { "has_strategy_brief": false, "has_strategy_structured": true, "has_vision": false, "has_kpi_targets": false, "has_kpi_results": false, "has_strategy_overview": true, "has_legislation_text": true, "has_legislation_structured": false, "has_global_initiatives_text": false, "has_global_initiatives_structured": false, "n_global_initiatives": 0, "has_ideas": true, "has_artifacts": true, "n_ideas": 12, "n_legislation": 0, "n_artifacts": 4, "n_kpi_targets": 0, "n_kpi_results": 0, "n_outcomes": 0, "verified_own_data": true }, "strategy_profile": { "status": "needs_review", "confidence": "medium", "summary": "", "official_site_url": "https://www.pbs.gov.au/info/healthpro/pharmaceutical-services-federal-committee-inquiry", "source_documents": [ { "type": "pb", "title": "Schedule of Pharmaceutical Benefits (Summary of Changes) (PDF 2MB)", "url": "https://www.pbs.gov.au/publication/schedule/2026/05/2026-05-01-general-soc.pdf", "period": "2026", "confidence": "medium" }, { "type": "pb", "title": "Covid 19 treatment - Paxlovid® (nirmatrelvir and ritonavir) PBS listing (PDF 244KB)", "url": "https://www.pbs.gov.au/publication/factsheets/covid-19-treatments/PBS-Factsheet-paxlovid-nirmatrelvir-and-ritonavir-updated-December-2024.pdf", "period": "2024", "confidence": "medium" } ], "purpose": null, "vision": null, "strategic_priorities": [], "values": [], "outcomes": [], "performance_measures": [], "document_alignment_terms": { "must_support": [], "watch_terms": [], "avoid_claiming_without_evidence": [] }, "review_note": "Structured strategy exists but is incomplete." }, "global_initiatives": null, "strategy": { "reporting_period": "2024-25", "corporate_plan_period": "2025-26", "vision": null, "vision_source_page": null, "purposes": null, "purposes_source_page": null, "how_we_deliver": null, "how_we_deliver_source_page": null, "government_priorities": [], "outcomes": [], "values": [], "values_framework_name": null, "kpi_targets_2025_26": [], "kpi_results_2024_25": [], "_source_urls": { "annual_report_url": "", "corporate_plan_url": "" } }, "ideas": [ { "entity_id": "B-002591", "entity_name": "Pharmaceutical Services Federal Committee of Inquiry", "folder_name": "Pharmaceutical-Services-Federal-Committee-of-Inquiry", "category": "Risk & Assurance", "scale": "small", "title": "Recommendation tracker for audits, reviews, and inquiries", "idea": "Publish a single internal tracker for audit/review recommendations, owners, due dates, and implementation evidence.", "quote": "Adults with COVID-19 confirmed by a nucleic acid test or a RAT can be prescribed PBS-subsidised\nPaxlovid by their doctor or authorised nurse practitioner if the patient is:\n• 50 years of age or older, with two additional risk factors for developing severe disease;\n• 30 years of age or older, identifying as First Nations people, with one risk factor for\ndeveloping severe disease;\n• 18 years of age or older, with moderate to severe immunocompromise; OR\n• 18 years of age or older who have been previously hospitalised from COVID-19 disease, if are\nsubsequently re-infected.", "impact": "High", "effort": "Low", "proof": "Evidence-backed", "beneficiaries": "Executives / assurance teams", "source": "pbs/2024.pdf (https://www.pbs.gov.au/publication/factsheets/covid-19-treatments/PBS-Factsheet-paxlovid-nirmatrelvir-and-ritonavir-updated-December-2024.pdf)", "implementation": [ "Pick one high-volume process or document family.", "Name an owner and baseline current volume, time, cost, and satisfaction.", "Run a 4-8 week pilot with clear before/after metrics.", "Publish lessons and decide whether to scale." ], "risks": [ "Privacy and data quality", "Change fatigue", "Unclear accountability", "Regulatory capture", "Over-automation of judgement" ] }, { "entity_id": "B-002591", "entity_name": "Pharmaceutical Services Federal Committee of Inquiry", "folder_name": "Pharmaceutical-Services-Federal-Committee-of-Inquiry", "category": "Risk & Assurance", "scale": "large", "title": "Integrated assurance and lessons-learned system", "idea": "Create an assurance system that connects audit findings, risk registers, delivery reviews, and investment decisions.", "quote": "Adults with COVID-19 confirmed by a nucleic acid test or a RAT can be prescribed PBS-subsidised\nPaxlovid by their doctor or authorised nurse practitioner if the patient is:\n• 50 years of age or older, with two additional risk factors for developing severe disease;\n• 30 years of age or older, identifying as First Nations people, with one risk factor for\ndeveloping severe disease;\n• 18 years of age or older, with moderate to severe immunocompromise; OR\n• 18 years of age or older who have been previously hospitalised from COVID-19 disease, if are\nsubsequently re-infected.", "impact": "Very High", "effort": "High", "proof": "Evidence-backed", "beneficiaries": "Executives / assurance teams", "source": "pbs/2024.pdf (https://www.pbs.gov.au/publication/factsheets/covid-19-treatments/PBS-Factsheet-paxlovid-nirmatrelvir-and-ritonavir-updated-December-2024.pdf)", "implementation": [ "Create a senior responsible owner and cross-functional delivery team.", "Map legislation, data, privacy, procurement, cyber, and workforce constraints.", "Co-design with users and frontline staff before technology selection.", "Stage delivery through pilots, benefits tracking, and public reporting." ], "risks": [ "Privacy and data quality", "Change fatigue", "Unclear accountability", "Regulatory capture", "Over-automation of judgement" ] }, { "entity_id": "B-002591", "entity_name": "Pharmaceutical Services Federal Committee of Inquiry", "folder_name": "Pharmaceutical-Services-Federal-Committee-of-Inquiry", "category": "Case Processing", "scale": "small", "title": "Triage queue for stuck or ageing cases", "idea": "Use existing case data to flag ageing, duplicate, incomplete, or high-risk cases for earlier intervention.", "quote": "The authority application must be made in writing and must include:\n(a) details of the proposed prescription(s); and\n(b) a completed authority application form relevant to the indication and treatment phase (the latest version is located on the\nwebsite specified in the Administrative Advice).\nteduglutide 5 mg injection [28 vials] (&) inert substance diluent [28 x 0.5 mL syringes], 1 pack\n11806J Max.Qty Packs No. of Rpts Premium $ DPMQ $ Brand Name and Manufacturer\n1 5 ..", "impact": "High", "effort": "Low", "proof": "Evidence-backed", "beneficiaries": "Applicants / case officers", "source": "other-pdfs/2026-05-01-general-schedule-Volume-2.pdf (https://www.pbs.gov.au/publication/schedule/2026/05/2026-05-01-general-schedule-Volume-2.pdf)", "implementation": [ "Pick one high-volume process or document family.", "Name an owner and baseline current volume, time, cost, and satisfaction.", "Run a 4-8 week pilot with clear before/after metrics.", "Publish lessons and decide whether to scale." ], "risks": [ "Privacy and data quality", "Change fatigue", "Unclear accountability" ] }, { "entity_id": "B-002591", "entity_name": "Pharmaceutical Services Federal Committee of Inquiry", "folder_name": "Pharmaceutical-Services-Federal-Committee-of-Inquiry", "category": "Case Processing", "scale": "large", "title": "End-to-end case processing redesign", "idea": "Redesign the case pathway around risk-based triage, reusable evidence, and automated eligibility checks.", "quote": "The authority application must be made in writing and must include:\n(a) details of the proposed prescription(s); and\n(b) a completed authority application form relevant to the indication and treatment phase (the latest version is located on the\nwebsite specified in the Administrative Advice).\nteduglutide 5 mg injection [28 vials] (&) inert substance diluent [28 x 0.5 mL syringes], 1 pack\n11806J Max.Qty Packs No. of Rpts Premium $ DPMQ $ Brand Name and Manufacturer\n1 5 ..", "impact": "Very High", "effort": "High", "proof": "Evidence-backed", "beneficiaries": "Applicants / case officers", "source": "other-pdfs/2026-05-01-general-schedule-Volume-2.pdf (https://www.pbs.gov.au/publication/schedule/2026/05/2026-05-01-general-schedule-Volume-2.pdf)", "implementation": [ "Create a senior responsible owner and cross-functional delivery team.", "Map legislation, data, privacy, procurement, cyber, and workforce constraints.", "Co-design with users and frontline staff before technology selection.", "Stage delivery through pilots, benefits tracking, and public reporting." ], "risks": [ "Privacy and data quality", "Change fatigue", "Unclear accountability" ] }, { "entity_id": "B-002591", "entity_name": "Pharmaceutical Services Federal Committee of Inquiry", "folder_name": "Pharmaceutical-Services-Federal-Committee-of-Inquiry", "category": "Citizen Services", "scale": "small", "title": "Plain-language service pages and proactive status updates", "idea": "Rewrite high-volume pages and letters into plain language, add status notifications, and measure contact reduction.", "quote": "[pages 28,29]\ns)\nAlternatively, applications for authority to prescribe can be submitted online using the form upload facility in Health\nProfessional Online Services (HPOS) at www.servicesaustralia.gov.au/hpos\nOr mailed to:\nServices Australia\nComplex Drugs\nReply Paid 9826\nHOBART TAS 7001\nAuthority required\nSevere aplastic anaemia\nTreatment Phase: Initial treatment - Second line treatment\nClinical criteria:\n• The condition must be severe aplastic anaemia, AND\n• Patient must not have achieved an adequate response to prior immunosuppressive therapy including anti-thymocyte\nantibody and ciclosporin; OR\n• Patient must have relapsed following prior immunosuppressive therapy including anti-thymocyte antibody and ciclosporin,\nAND\n• Patient must not receive more than 16 weeks of treatment under this restriction.", "impact": "High", "effort": "Low", "proof": "Evidence-backed", "beneficiaries": "Citizens / service users", "source": "other-pdfs/2026-05-01-general-schedule-Volume-2.pdf (https://www.pbs.gov.au/publication/schedule/2026/05/2026-05-01-general-schedule-Volume-2.pdf)", "implementation": [ "Pick one high-volume process or document family.", "Name an owner and baseline current volume, time, cost, and satisfaction.", "Run a 4-8 week pilot with clear before/after metrics.", "Publish lessons and decide whether to scale." ], "risks": [ "Privacy and data quality", "Change fatigue", "Unclear accountability", "Digital exclusion", "Low public trust if feedback is not acted on" ] }, { "entity_id": "B-002591", "entity_name": "Pharmaceutical Services Federal Committee of Inquiry", "folder_name": "Pharmaceutical-Services-Federal-Committee-of-Inquiry", "category": "Citizen Services", "scale": "large", "title": "Single front door for life-event based services", "idea": "Bundle services around life events so citizens can complete related steps across agencies in one journey.", "quote": "[pages 28,29]\ns)\nAlternatively, applications for authority to prescribe can be submitted online using the form upload facility in Health\nProfessional Online Services (HPOS) at www.servicesaustralia.gov.au/hpos\nOr mailed to:\nServices Australia\nComplex Drugs\nReply Paid 9826\nHOBART TAS 7001\nAuthority required\nSevere aplastic anaemia\nTreatment Phase: Initial treatment - Second line treatment\nClinical criteria:\n• The condition must be severe aplastic anaemia, AND\n• Patient must not have achieved an adequate response to prior immunosuppressive therapy including anti-thymocyte\nantibody and ciclosporin; OR\n• Patient must have relapsed following prior immunosuppressive therapy including anti-thymocyte antibody and ciclosporin,\nAND\n• Patient must not receive more than 16 weeks of treatment under this restriction.", "impact": "Very High", "effort": "High", "proof": "Evidence-backed", "beneficiaries": "Citizens / service users", "source": "other-pdfs/2026-05-01-general-schedule-Volume-2.pdf (https://www.pbs.gov.au/publication/schedule/2026/05/2026-05-01-general-schedule-Volume-2.pdf)", "implementation": [ "Create a senior responsible owner and cross-functional delivery team.", "Map legislation, data, privacy, procurement, cyber, and workforce constraints.", "Co-design with users and frontline staff before technology selection.", "Stage delivery through pilots, benefits tracking, and public reporting." ], "risks": [ "Privacy and data quality", "Change fatigue", "Unclear accountability", "Digital exclusion", "Low public trust if feedback is not acted on" ] }, { "entity_id": "B-002591", "entity_name": "Pharmaceutical Services Federal Committee of Inquiry", "folder_name": "Pharmaceutical-Services-Federal-Committee-of-Inquiry", "category": "Staff Productivity", "scale": "small", "title": "Reusable briefing and summary assistant for internal documents", "idea": "Create controlled templates for summarising reports, submissions, minutes, and ministerial briefs.", "quote": "[pages 56,57]\nment must be: (i) the sole PBS-subsidised proton pump inhibitor (PPI) for this condition, (ii) the sole strength of\nthis PPI, (iii) the sole form of PPI, AND\n• Patient must must have symptoms inadequately controlled with each of: (i) a standard dose proton pump inhibitor (PPI)\nadministered once daily, (ii) a low dose PPI administered twice daily; treatment is for: (1) establishment of symptom\ncontrol; OR\n• Patient must be assessed for the risks/benefits of a step-down in dosing from standard dose PPI administered twice daily,\nwith the determination being that the risks outweigh the benefits; treatment is for: (2) maintenance treatment; OR\n• Patient must have trialled a step-down in dosing, yet symptoms have re-emerged/worsened; treatment is for: (3) re-\nestablishment of symptom control; OR", "impact": "High", "effort": "Low", "proof": "Evidence-backed", "beneficiaries": "APS staff / executives", "source": "other-pdfs/2026-05-01-general-schedule-Volume-1.pdf (https://www.pbs.gov.au/publication/schedule/2026/05/2026-05-01-general-schedule-Volume-1.pdf)", "implementation": [ "Pick one high-volume process or document family.", "Name an owner and baseline current volume, time, cost, and satisfaction.", "Run a 4-8 week pilot with clear before/after metrics.", "Publish lessons and decide whether to scale." ], "risks": [ "Privacy and data quality", "Change fatigue", "Unclear accountability", "Sensitive information leakage", "Inconsistent quality of generated drafts" ] }, { "entity_id": "B-002591", "entity_name": "Pharmaceutical Services Federal Committee of Inquiry", "folder_name": "Pharmaceutical-Services-Federal-Committee-of-Inquiry", "category": "Staff Productivity", "scale": "large", "title": "Department-wide knowledge and briefing platform", "idea": "Build a secure knowledge platform that lets staff search, summarise, and cite approved departmental material.", "quote": "[pages 56,57]\nment must be: (i) the sole PBS-subsidised proton pump inhibitor (PPI) for this condition, (ii) the sole strength of\nthis PPI, (iii) the sole form of PPI, AND\n• Patient must must have symptoms inadequately controlled with each of: (i) a standard dose proton pump inhibitor (PPI)\nadministered once daily, (ii) a low dose PPI administered twice daily; treatment is for: (1) establishment of symptom\ncontrol; OR\n• Patient must be assessed for the risks/benefits of a step-down in dosing from standard dose PPI administered twice daily,\nwith the determination being that the risks outweigh the benefits; treatment is for: (2) maintenance treatment; OR\n• Patient must have trialled a step-down in dosing, yet symptoms have re-emerged/worsened; treatment is for: (3) re-\nestablishment of symptom control; OR", "impact": "Very High", "effort": "High", "proof": "Evidence-backed", "beneficiaries": "APS staff / executives", "source": "other-pdfs/2026-05-01-general-schedule-Volume-1.pdf (https://www.pbs.gov.au/publication/schedule/2026/05/2026-05-01-general-schedule-Volume-1.pdf)", "implementation": [ "Create a senior responsible owner and cross-functional delivery team.", "Map legislation, data, privacy, procurement, cyber, and workforce constraints.", "Co-design with users and frontline staff before technology selection.", "Stage delivery through pilots, benefits tracking, and public reporting." ], "risks": [ "Privacy and data quality", "Change fatigue", "Unclear accountability", "Sensitive information leakage", "Inconsistent quality of generated drafts" ] }, { "entity_id": "B-002591", "entity_name": "Pharmaceutical Services Federal Committee of Inquiry", "folder_name": "Pharmaceutical-Services-Federal-Committee-of-Inquiry", "category": "Data & Performance", "scale": "small", "title": "KPI evidence register with named owners", "idea": "Create a simple register mapping each KPI to source data, owner, frequency, target, and last result.", "quote": "Where applications (either on the same day or on separate days) for multiple strengths\nare sought with an intent to titrate patient's dosage, repeats should only be sought for the listed target strength\n18 Schedule of Pharmaceutical Benefits – May 2026", "impact": "High", "effort": "Low", "proof": "Evidence-backed", "beneficiaries": "Executives / Parliament / public", "source": "pbs/2026.pdf (https://www.pbs.gov.au/publication/schedule/2026/05/2026-05-01-general-soc.pdf)", "implementation": [ "Pick one high-volume process or document family.", "Name an owner and baseline current volume, time, cost, and satisfaction.", "Run a 4-8 week pilot with clear before/after metrics.", "Publish lessons and decide whether to scale." ], "risks": [ "Privacy and data quality", "Change fatigue", "Unclear accountability" ] }, { "entity_id": "B-002591", "entity_name": "Pharmaceutical Services Federal Committee of Inquiry", "folder_name": "Pharmaceutical-Services-Federal-Committee-of-Inquiry", "category": "Data & Performance", "scale": "large", "title": "Outcome dashboard linking budget, delivery, and public impact", "idea": "Build a public-facing outcome dashboard showing spend, outputs, outcomes, and delivery confidence.", "quote": "Where applications (either on the same day or on separate days) for multiple strengths\nare sought with an intent to titrate patient's dosage, repeats should only be sought for the listed target strength\n18 Schedule of Pharmaceutical Benefits – May 2026", "impact": "Very High", "effort": "High", "proof": "Evidence-backed", "beneficiaries": "Executives / Parliament / public", "source": "pbs/2026.pdf (https://www.pbs.gov.au/publication/schedule/2026/05/2026-05-01-general-soc.pdf)", "implementation": [ "Create a senior responsible owner and cross-functional delivery team.", "Map legislation, data, privacy, procurement, cyber, and workforce constraints.", "Co-design with users and frontline staff before technology selection.", "Stage delivery through pilots, benefits tracking, and public reporting." ], "risks": [ "Privacy and data quality", "Change fatigue", "Unclear accountability" ] }, { "entity_id": "B-002591", "entity_name": "Pharmaceutical Services Federal Committee of Inquiry", "folder_name": "Pharmaceutical-Services-Federal-Committee-of-Inquiry", "category": "Regulation & Policy", "scale": "small", "title": "Regulatory burden scan for forms, guidance, and reporting", "idea": "Identify the top 10 highest-friction reporting obligations and simplify guidance, forms, or evidence requirements.", "quote": "The aim of the National Medicines Policy is to meet medication and related service\nneeds, so that both optimal health outcomes and economic objectives are achieved.", "impact": "Medium", "effort": "Low", "proof": "Evidence-backed", "beneficiaries": "Regulated entities / policy teams", "source": "pages/about.html (https://www.pbs.gov.au/info/about-the-pbs)", "implementation": [ "Pick one high-volume process or document family.", "Name an owner and baseline current volume, time, cost, and satisfaction.", "Run a 4-8 week pilot with clear before/after metrics.", "Publish lessons and decide whether to scale." ], "risks": [ "Privacy and data quality", "Change fatigue", "Unclear accountability", "Regulatory capture", "Over-automation of judgement" ] }, { "entity_id": "B-002591", "entity_name": "Pharmaceutical Services Federal Committee of Inquiry", "folder_name": "Pharmaceutical-Services-Federal-Committee-of-Inquiry", "category": "Regulation & Policy", "scale": "large", "title": "Adaptive regulation program with live feedback loops", "idea": "Create an adaptive regulation model using sandboxes, industry data, risk scoring, and regular rule updates.", "quote": "The aim of the National Medicines Policy is to meet medication and related service\nneeds, so that both optimal health outcomes and economic objectives are achieved.", "impact": "High", "effort": "High", "proof": "Evidence-backed", "beneficiaries": "Regulated entities / policy teams", "source": "pages/about.html (https://www.pbs.gov.au/info/about-the-pbs)", "implementation": [ "Create a senior responsible owner and cross-functional delivery team.", "Map legislation, data, privacy, procurement, cyber, and workforce constraints.", "Co-design with users and frontline staff before technology selection.", "Stage delivery through pilots, benefits tracking, and public reporting." ], "risks": [ "Privacy and data quality", "Change fatigue", "Unclear accountability", "Regulatory capture", "Over-automation of judgement" ] } ], "legislation_administered": [], "artifacts": [ { "category": "pbs", "year": "2026", "url": "https://www.pbs.gov.au/publication/schedule/2026/05/2026-05-01-general-soc.pdf", "file": "pbs/2026.pdf", "bytes": 371591, "link_text": "Schedule of Pharmaceutical Benefits (Summary of Changes) (PDF 2MB)" }, { "category": "pbs", "year": "2024", "url": "https://www.pbs.gov.au/publication/factsheets/covid-19-treatments/PBS-Factsheet-paxlovid-nirmatrelvir-and-ritonavir-updated-December-2024.pdf", "file": "pbs/2024.pdf", "bytes": 251055, "link_text": "Covid 19 treatment - Paxlovid® (nirmatrelvir and ritonavir) PBS listing (PDF 244KB)" }, { "category": "other-pdfs", "year": "2026", "url": "https://www.pbs.gov.au/publication/schedule/2026/05/2026-05-01-general-schedule-Volume-1.pdf", "file": "other-pdfs/2026-05-01-general-schedule-Volume-1.pdf", "bytes": 14155691, "link_text": "Schedule of Pharmaceutical Benefits (Volume 1 - General Schedule) (PDF 20MB)" }, { "category": "other-pdfs", "year": "2026", "url": "https://www.pbs.gov.au/publication/schedule/2026/05/2026-05-01-general-schedule-Volume-2.pdf", "file": "other-pdfs/2026-05-01-general-schedule-Volume-2.pdf", "bytes": 9898431, "link_text": "Schedule of Pharmaceutical Benefits (Volume 2 - Section 100) (PDF 10MB)" } ], "_meta": { "snapshot_built_at": "2026-05-14T02:13:32+00:00", "strategy_brief_meta": { "model": "nova-micro", "folder": "Pharmaceutical-Services-Federal-Committee-of-Inquiry", "annual_report": { "file": null, "url": "", "year": null }, "corporate_plan": { "file": "other-pdfs\\2026-05-01-general-schedule-Volume-1.txt", "url": "https://www.pbs.gov.au/publication/schedule/2026/05/2026-05-01-general-schedule-Volume-1.pdf", "year": "2026-05-01-general-schedule-Volume-1" }, "usage": { "input_tokens": 18244, "output_tokens": 155, "total_tokens": 18399, "model": "nova-micro" }, "cost_usd": 0.0006602400000000001, "elapsed_seconds": 7.19, "generated_at": "2026-05-13T05:18:18+00:00" }, "ideas_manifest": { "entity_id": "B-002591", "entity_name": "Pharmaceutical Services Federal Committee of Inquiry", "folder_name": "Pharmaceutical-Services-Federal-Committee-of-Inquiry", "generated_at": "2026-05-09T23:05:37.944219+00:00", "idea_count": 12, "markdown": "ideas/Pharmaceutical-Services-Federal-Committee-of-Inquiry_ideas.md", "jsonl": "ideas/ideas.jsonl", "inputs": [ "Pharmaceutical-Services-Federal-Committee-of-Inquiry_strategy-overview.md", "strategy-evidence.json", "global-intelligence/source-manifest.json" ] }, "global_intel_meta": null } }